Fifth Medical Clinic
Mannheim, Baden-Wurttemberg, 68167, Germany
NCT Number: NCT00401453
Insulin resistance is a central feature of Diabetes mellitus type 2 (Stumvoll et al. 2005). Hypo- and hyperglycemic states are associated with adverse inpatient outcomes (ADA et al. 2006 Diab Care) and with the development of microvascular complications (UKPDS 34 Lancet 1998).
A long known therapy for the acute treatment of patients with deteriorated glucose metabolism and insulin resistance are carbohydrate days. The principle of the therapy was firstly introduced in 1903 by Carl von Noorden (Noorden et al. 1903). The diabetic patients were treated for several days with a carbohydrate rich diet with fat restriction. Surprisingly, this resulted in an amelioration of glucosuria. Today it's still a valuable tool for patients with uncontrollable diabetes mellitus and severe insulin resistance (Willms B. 1989). But up to now there has been no systemic evaluation of carbohydrate days in patients with deteriorated Diabetes mellitus and insulin resistance.
The investigators conducted a pilot study with 14 patients to evaluate the efficacy of two days of oatmeal on insulin resistance and glucose metabolism in an acute clinical setting and after a four week outpatient period. Inclusion criteria were type 2 diabetes with deteriorated glucose metabolism, insulin resistance defined as an insulin dosage of more than 1 U per day and kg bodyweight. Within this pilot trial the investigators found a marked decrease of insulin requirements (~40%) and mean daily blood glucose to a mean blood glucose of 114.7±36.7 mg/dl in the acute setting as well as after the four week outpatient period (Lammert et al. 2006).
The most important shortcomings of this study were the hypocaloric interventions in both groups (diabetes-adapted diet: 1500kcal/d vs. oatmeal 1200kcal/d) making it difficult to attribute the observed effects to oatmeal alone as well as the uncontrolled nature. These design flaws have been addressed within this new clinical trial. The investigators plan an open label, cross-over study with isocaloric interventions (oatmeal and diabetes-adapted diet: ~ 1200kcal/d). The intervention comprises two days of oatmeal (third and fourth day) within a 5 day hospital stay. The control is only treated with 5 days of diabetes adapted diet. Thereafter, the patients are followed every four weeks for an overall of 16 weeks.
Looking for future studies?
Notify Me18 year–80 year
All sexes
Interventional
Phase 3
Mannheim, Baden-Wurttemberg, 68167, Germany
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Dietary intervention with two days of oatmeal compared to normal diabetes adapted diet in insulin resistant subjects.
Time frame: directly before and after intervention as well as 4, 8, 12, and 16 weeks after intervention
Time frame: directly before and after intervention as well as 4, 8, 12, and 16 weeks after intervention
Time frame: directly before and after intervention as well as 4, 8, 12, and 16 weeks after intervention
Time frame: directly before and after intervention as well as 4, 8, 12, and 16 weeks after intervention
Time frame: directly before and after intervention as well as 4, 8, 12, and 16 weeks after intervention
Universitätsmedizin Mannheim
Other
Carbohydrate Days as Simple and Efficient Therapy for Patients With Type 2 Diabetes Mellitus and Insulin Resistance: Oatmeal and Insulin Resistance (OMA-IR).
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT01336777
Body Weight, Diabetes Mellitus
Stanford, California, United States
View Trial DetailsNCT02258698
Diabetes Mellitus, Diabetes Mellitus Type 2
Basel, Canton of Basel-City, Switzerland
View Trial DetailsNCT02863276
Diabetes Mellitus, Diabetes Mellitus Type 2
View Trial DetailsNCT01121172
Body Weight, Diabetes Mellitus
Thessaloniki, Greece
View Trial Details